Press Release

Printer Friendly Version View printer-friendly version
Back

Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective March 31, 2017, as part of Russell’s quarterly additions of companies with recent initial public offerings.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes.  The Russell Microcap® Index represents 2,000 small cap and micro-cap stocks that captures the smallest 1,000 companies in the Russell 2000®, in addition to 1,000 smaller U.S.- based listed stocks.

Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell Investments determines membership for each index based on objective market capitalization rankings and style attributes.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/

Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com 

Primary Logo

Jounce Therapeutics, Inc.